Iberdomide with dexamethasone for R/R multiple myeloma

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM...Подробнее

Iberdomide plus dexamethasone for heavily pretreated multiple myelomaПодробнее

Phase Ib/IIa study of iberdomide, in combination with dexamethasone, in patients with RRMMПодробнее

Iberdomide + dexamethasone in R/R multiple myelomaПодробнее

Iberdomide in combination with dexamethasone for multiple myelomaПодробнее

Iberdomide-based regimens in R/R multiple myelomaПодробнее

CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myelomaПодробнее

CC-220-MM-001: IberDd, IberVd and IbrKd for R/R myelomaПодробнее

Iberdomide in Combination with DEX in pts with RRMM: Results from the CC-220-MM-001 TrialПодробнее

Iberdomide in Combination with Dex and Dara, Bort, or Cfz in Pts with RRMMПодробнее

The efficacy & role of iberdomide in R/R multiple myelomaПодробнее

Update on iberdomide treatment combinations in R/R myelomaПодробнее

First clinical study of iberdomide, a CELMoD, in pts with relapsed/refractory multiple myelomaПодробнее

A trial investigating IberVd in transplant-ineligible newly diagnosed multiple myelomaПодробнее

A Phase I/II trial of iberdomide for the treatment of intermediate- or high-risk smoldering myelomaПодробнее

Safety and efficacy of iberdomide + dexamethasone in patients with triple-class refractory myelomaПодробнее

R/R myeloma: iberdomide, dex & dara or bortezomibПодробнее